EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Elevated SLC3A2 Expression Promotes the Progression of Gliomas and Enhances Ferroptosis Resistance through the AKT/NRF2/GPX4 Axis

Yuqian Zheng, Shaolong Zhou, Yiran Tao, Zimin Shi, Xiang Li, Xudong Fu, Jian Ma, Weihua Hu, Wulong Liang, Xinjun Wang

Cancer Research and Treatment · 15.01.2026 · 58 (1) · 71-94

DOI: 10.4143/crt.2024.933 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Research and Treatment, erschienen am 15.01.2026. Verfasst von Yuqian Zheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Ferroptosis, Glioma, NF-E2-Related Factor 2, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Natural Science Foundation of China, Henan Province key research and development and promotion special, Henan Zhongyuan Talent Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The aim of this study is to determine the impact of solute carrier family 3 member 2 (SLC3A2) on the malignant phenotype of gliomas and its role in regulating ferroptosis sensitivity.Materials and Methods The malignant phenotype of glioma was assessed by cell proliferation assay, colony formation assay, EdU assay, wound healing, and Transwell experiments. We further validated the impact of reduced SLC3A2 expression on the sensitivity to ferroptosis in glioma cells through Cell Counting Kit-8 assays, flow cytometry, western blotting, and transmission electron microscopy. Western blot was used to explore how SLC3A2 affects glioma sensitivity to ferroptosis through the AKT/NF-E2-related factor 2 (NRF2)/glutathione peroxidase 4 (GPX4) axis. By establishing a subcutaneous xenograft tumor model in BALB/c-nude mice, we investigated the growth of tumors following the knockout of SLC3A2 in glioma cells.

Results

Downregulation of SLC3A2 suppressed the malignant phenotype of glioma by blocking the cell cycle and epithelial-mesenchymal transition processes. On the other hand, loss of SLC3A2 not only downregulated SLC7A11 but also prevented the activation of the AKT/NRF2/GPX4 axis. These lead to increased accumulation of reactive oxygen species and lipid peroxides, ultimately enhancing the susceptibility of glioma to ferroptosis.

Conclusion

Our findings suggest that SLC3A2 is an oncogene in gliomas, promoting their occurrence and development. It plays a critical role in ferroptosis resistance through the AKT/NRF2/GPX4 axis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisGliomaNF-E2-Related Factor 2Proto-Oncogene Proteins c-aktPhospholipid Hydroperoxide Glutathione PeroxidaseBrain NeoplasmsFusion Regulatory Protein 1, Heavy ChainAnimalsHumansMiceCell Line, TumorMice, Inbred BALB CGene Expression Regulation, NeoplasticCell ProliferationDisease ProgressionMice, NudeSignal TransductionXenograft Model Antitumor Assays

Stichwörter der Autor:innen

FerroptosisGliomaSLC3A2Therapeutic sensitivity

Substanzen

NF-E2-Related Factor 2Proto-Oncogene Proteins c-aktPhospholipid Hydroperoxide Glutathione PeroxidaseSLC3A2 protein, humanNFE2L2 protein, humanFusion Regulatory Protein 1, Heavy Chain

Autor:innen und Institutionen

  • Department of Neurosurgery, The Fifth Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Department of Neurosurgery, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Henan International Joint Laboratory of Glioma Metabolism and Microenvironment Research, Zhengzhou, China.
  • Maternal and Child Neurological Disorders International Joint Research Center, Zhengzhou, China.
  • Tianjian Laboratory of Advanced Biomedical Sciences, School of Life Sciences, Zhengzhou University, Zhengzhou, China.

Förderung

  • National Natural Science Foundation of China
  • Henan Province key research and development and promotion special
  • Henan Zhongyuan Talent Program
  • Science and technology of Henan Province
  • Henan Provincial Health Commission
  • Henan Provincial Department of Science and Technology
  • Health Commission of Henan Province
  • Fifth Affiliated Hospital of Zhengzhou University

Zitieren

APA

Zheng, Y., Zhou, S., Tao, Y., Shi, Z., Li, X., Fu, X., Ma, J., Hu, W., Liang, W., & Wang, X. (2026). Elevated SLC3A2 Expression Promotes the Progression of Gliomas and Enhances Ferroptosis Resistance through the AKT/NRF2/GPX4 Axis. Cancer Research and Treatment, 58(1), 71-94. https://doi.org/10.4143/crt.2024.933

Vancouver

Zheng Y, Zhou S, Tao Y, Shi Z, Li X, Fu X, et al. Elevated SLC3A2 Expression Promotes the Progression of Gliomas and Enhances Ferroptosis Resistance through the AKT/NRF2/GPX4 Axis. Cancer Research and Treatment. 2026;58(1):71-94. doi:10.4143/crt.2024.933

BibTeX
@article{Zheng2026,
  author = {Zheng, Yuqian and Zhou, Shaolong and Tao, Yiran and Shi, Zimin and Li, Xiang and Fu, Xudong and Ma, Jian and Hu, Weihua and Liang, Wulong and Wang, Xinjun},
  title = {Elevated SLC3A2 Expression Promotes the Progression of Gliomas and Enhances Ferroptosis Resistance through the AKT/NRF2/GPX4 Axis},
  journal = {Cancer Research and Treatment},
  year = {2026},
  volume = {58},
  number = {1},
  pages = {71--94},
  doi = {10.4143/crt.2024.933}
}
Kostenlos starten →